Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma
暂无分享,去创建一个
Biwei Yang | J. Xia | F. Qi | Lingxiao Wang | Peixin Huang | Zhiying Zhao
[1] S. Opal,et al. Anti-inflammatory cytokines. , 2000, Chest.
[2] T. Patel. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.
[3] Christian von Mering,et al. STRING: a database of predicted functional associations between proteins , 2003, Nucleic Acids Res..
[4] G. Salles,et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.
[5] M. Chou,et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. , 2005, Lung cancer.
[6] Ziv Bar-Joseph,et al. STEM: a tool for the analysis of short time series gene expression data , 2006, BMC Bioinformatics.
[7] E. Nkenke,et al. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. , 2008, Anticancer research.
[8] Jianren Gu,et al. Ciliary neurotrophic factor receptor α subunit–modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications , 2007, Hepatology.
[9] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[10] H. Yoshikawa,et al. Interleukin-10 -1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. , 2010, Japanese journal of clinical oncology.
[11] T. Mcclanahan,et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.
[12] Francis J. Huber,et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. , 2011, Immunity.
[13] X. Bai,et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. , 2012, Cancer research.
[14] Yozo Sato,et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602 , 2013, Upsala journal of medical sciences.
[15] Seungok Lee,et al. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. , 2013, Cytokine.
[16] Qi Zhang,et al. Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. , 2013, Carcinogenesis.
[17] P. Zou,et al. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. , 2013, Gene.
[18] F. Gounari,et al. Current status of interleukin-10 and regulatory T-cells in cancer , 2013, Current opinion in oncology.
[19] T. Utsunomiya,et al. High STAT4 Expression is a Better Prognostic Indicator in Patients with Hepatocellular Carcinoma After Hepatectomy , 2014, Annals of Surgical Oncology.
[20] Á. Mena,et al. Factors associated with recurrence and survival in liver transplant patients with HCC--a single center retrospective study. , 2015, Annals of hepatology.
[21] Wesam A. Nasif,et al. Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response , 2015, Disease markers.
[22] Jin Hyoung Kim,et al. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. , 2015, World journal of gastroenterology.
[23] J. Gray,et al. IL-10 and integrin signaling pathways are associated with head and neck cancer progression , 2016, BMC Genomics.
[24] L. Kenner,et al. JAK-STAT signaling in cancer: From cytokines to non-coding genome. , 2016, Cytokine.
[25] Luc Girard,et al. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.
[26] Weiqi Wang,et al. Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity , 2016, Scientific Reports.
[27] R. Li,et al. Semi-quantitative assessment of the presence and Child-Pugh class of hepatitis B related cirrhosis by using liver lobe-based dynamic contrast-enhanced MRI. , 2016, Clinical radiology.
[28] C. Trautwein,et al. Functional role of CCL5/RANTES for HCC progression during chronic liver disease. , 2017, Journal of hepatology.
[29] T. Gamblin,et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[30] M. Honda,et al. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study , 2017, BMC Cancer.
[31] Moudi Al-Nashmi,et al. Interleukin 1 receptor antagonist and 2'-5'-oligoadenylate synthetase-like molecules as novel biomarkers for multiple sclerosis patients in Bahrain. , 2017, Multiple sclerosis and related disorders.
[32] Ke Chen,et al. Human MSCs promotes colorectal cancer epithelial–mesenchymal transition and progression via CCL5/β-catenin/Slug pathway , 2017, Cell Death and Disease.
[33] Priya Bhardwaj,et al. Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF , 2017, Nature Cell Biology.
[34] Mingxia Cui,et al. Ciliary neurotrophic factor analogue aggravates CCl4-induced acute hepatic injury in rats. , 2017, Canadian journal of physiology and pharmacology.
[35] I. Ellis,et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients , 2017, Cancer Immunology, Immunotherapy.
[36] C. Sirlin,et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis , 2017, Abdominal Radiology.
[37] T. Pawlik,et al. Personalized treatment of patients with very early hepatocellular carcinoma. , 2017, Journal of hepatology.
[38] Fernando Alarid-Escudero,et al. An Overview of R in Health Decision Sciences , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[39] Minoru Kanehisa,et al. KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..
[40] R. Sacco,et al. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review , 2017, Journal of hepatocellular carcinoma.
[41] Qi Zhang,et al. Hypoxia‐inducible factor‐1α/interleukin‐1β signaling enhances hepatoma epithelial–mesenchymal transition through macrophages in a hypoxic‐inflammatory microenvironment , 2018, Hepatology.
[42] Linyan Zhu,et al. Activation of ClC‐3 chloride channel by 17β‐estradiol relies on the estrogen receptor α expression in breast cancer , 2018, Journal of cellular physiology.
[43] T. Luedde,et al. IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies , 2018, International journal of molecular sciences.
[44] Xiaoya Yang,et al. Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer , 2018, Journal of Hematology & Oncology.
[45] R. Medeiros,et al. Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort , 2018, The Pharmacogenomics Journal.
[46] R. Coletta,et al. Clinicopathological significance of chemokine receptor (CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4) expression in head and neck squamous cell carcinomas , 2018, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[47] C. Corrigan,et al. Expression of IL-17A, E, and F and their receptors in non-small-cell lung cancer. , 2018, Journal of biological regulators and homeostatic agents.
[48] I. Holen,et al. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment , 2019, Clinical Cancer Research.
[49] H. Simon,et al. IL-37: A new player in the chronic rhinosinusitis arena. , 2019, The Journal of allergy and clinical immunology.
[50] T. de Baère,et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.
[51] Mai Moaaz,et al. Th17/Treg cells imbalance and their related cytokines (IL-17, IL-10 and TGF-β) in children with autism spectrum disorder , 2019, Journal of Neuroimmunology.
[52] E. Tinazzi,et al. In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis , 2019, Journal of clinical medicine.
[53] E. Suzuki,et al. Paracoccidioides species present distinct fungal adherence to epithelial lung cells and promote different IL-8 secretion levels , 2019, Medical Microbiology and Immunology.
[54] T. Chan,et al. High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas. , 2019, Urologic oncology.
[55] She Chen,et al. TREM2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K/Akt/β-catenin pathway , 2019, Oncogenesis.
[56] K. Goswami,et al. TNF‐α mediated MEK–ERK signaling in invasion with putative network involving NF‐κB and STAT‐6: a new perspective in glioma , 2019, Cell biology international.